June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Re-treatments after laser coagulation or anti-VEGF injections in infants treated for retinopathy of prematurity – data from the German ROP registry
Johanna Madeleine Pfeil; Teresa Barth; Wolf Lagrèze; Birgit Lorenz; Karsten Hufendiek; Raffael Liegl; Helge Breuss; Sebastian Bemme; Jakob Ferdinand Meyer; Barbara Glitz; Daniela Suesskind; Ameli Gabel-Pfisterer; Christos Skevas; Tim U Krohne; Vinodh Kakkassery; Andreas Stahl
Author Affiliations & Notes
  • Johanna Madeleine Pfeil
    Department of Ophthalmology, Universitatsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  • Teresa Barth
    Department of Ophthalmology, Universitat Regensburg, Regensburg, Bayern, Germany
  • Wolf Lagrèze
    Department of Ophthalmology, Albert-Ludwigs-Universitat Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany
  • Birgit Lorenz
    Department of Ophthalmology, Justus Liebig Universitat Giessen, Giessen, Hessen, Germany
  • Karsten Hufendiek
    Department of Ophthalmology, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
  • Raffael Liegl
    Department of Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Helge Breuss
    Department of Ophthalmology, HELIOS Klinikum Berlin-Buch, Berlin, Berlin, Germany
  • Sebastian Bemme
    Department of Ophthalmology, Georg-August-Universitat Gottingen, Gottingen, Niedersachsen, Germany
  • Jakob Ferdinand Meyer
    Department of Ophthalmology, Vivantes Klinikum Neukolln, Berlin, Berlin, Germany
  • Barbara Glitz
    Department of Ophthalmology, University of Munster Medical Center, Muenster, Germany
  • Daniela Suesskind
    Department of Ophthalmology, Eberhard Karls Universitat Tubingen, Tubingen, Baden-Württemberg, Germany
  • Ameli Gabel-Pfisterer
    Department of Ophthalmology, Klinikum Ernst von Bergmann gGmbH, Potsdam, Brandenburg, Germany
  • Christos Skevas
    Department of Ophthalmology, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany
  • Tim U Krohne
    Department of Ophthalmology, Universitat zu Koln, Koln, Nordrhein-Westfalen, Germany
  • Vinodh Kakkassery
    Department of Ophthalmology, Universitat zu Lubeck Sektion Medizin, Lubeck, Schleswig-Holstein, Germany
  • Andreas Stahl
    Department of Ophthalmology, Universitatsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  • Footnotes
    Commercial Relationships   Johanna Pfeil None; Teresa Barth None; Wolf Lagrèze None; Birgit Lorenz None; Karsten Hufendiek Novartis, Code C (Consultant/Contractor); Raffael Liegl Novartis, Allergan, Code C (Consultant/Contractor), DORC, Code R (Recipient); Helge Breuss None; Sebastian Bemme None; Jakob Meyer None; Barbara Glitz None; Daniela Suesskind None; Ameli Gabel-Pfisterer None; Christos Skevas None; Tim Krohne AlimeraSciences, Bayer, Novartis, Roche, Code C (Consultant/Contractor), Bayer, Novartis, Code F (Financial Support), AlimeraSciences, Allergan, Bayer, Heidelberg Engineering, Novartis, Roche, Code R (Recipient); Vinodh Kakkassery Novartis, Code C (Consultant/Contractor), Novartis, Code R (Recipient); Andreas Stahl Novartis, Bayer, Code F (Financial Support), Novartis, Bayer, Roche, Alcon, Code R (Recipient), Speaker of the Board of retina.net e.V. Germany and Member of the Board of the GermanRetina Society, Code S (non-remunerative)
  • Footnotes
    Support  Retina.net and Jackstaedt foundation
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4198 – F0258. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Re-treatments after laser coagulation or anti-VEGF injections in infants treated for retinopathy of prematurity – data from the German ROP registry
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Johanna Madeleine Pfeil, Teresa Barth, Wolf Lagrèze, Birgit Lorenz, Karsten Hufendiek, Raffael Liegl, Helge Breuss, Sebastian Bemme, Jakob Ferdinand Meyer, Barbara Glitz, Daniela Suesskind, Ameli Gabel-Pfisterer, Christos Skevas, Tim U Krohne, Vinodh Kakkassery, Andreas Stahl; Re-treatments after laser coagulation or anti-VEGF injections in infants treated for retinopathy of prematurity – data from the German ROP registry. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4198 – F0258.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : The German ROP registry collects real-life data on infants treated for retinopathy of prematurity (ROP). This is of particular importance in light of the new treatment option of anti-VEGF for ROP. This abstract compares the re-treatment rates of anti-VEGF versus laser in ROP.

Methods : We analyzed data from 353 infants (692 treated eyes) born between 2011 and 2020. Descriptive statistics were used to analyze the percentage of eyes needing at least one re-treatment. Infants with a need for re-treatment were compared to infants without need for re-treatment regarding demographics (birthweight, gestational age (GA) at birth, postnatal age (PNA) as well as postmenstrual age (PMA) at treatment; t-tests). The interval between initial treatment and re-treatment was compared between different treatment groups (laser, bevacizumab (bvz), ranibizumab (rbz)).

Results : Of the 692 treated eyes 108 eyes (15.6%) needed at least one re-treatment. Re-treatment rates varied between 11.6 and 30.6% during the observation period. Of eyes initially treated with laser (396) 14% were re-treated compared to 12% of eyes treated with bevacizumab (117) and 24.5% of eyes treated with ranibizumab (159). Laser treated eyes were re-treated after a mean of 22 days, which was significantly shorter than after bvz (mean 53; p=0.0004) or rbz (mean 55; p<0.0001). A second re-treatment was conducted in a total of 28 eyes after a mean of 40 days after the first re-treatment in the laser group, 61 days in the bvz group and 47 days in the rbz group. Infants who needed at least one re-treatment were significantly lighter at birth (614g vs. 709g; p=0.0021), were born with a lower GA (24.8 vs. 25.5 weeks; p=0.0128), had lower PMA at treatment (36.3 vs. 38 weeks; p<0.0001) and lower PNA at treatment (11.5 vs. 12.6 weeks; p=0.0086) compared to infants who did not require re-treatment.

Conclusions : Among the group of infants with treatment requiring ROP, infants with lower GA and birth weight have the highest risk for requiring more than one ROP treatment. Re-treatment rates were higher after initial treatment with rbz and occurred later with rbz or bvz compared to laser. Real life data from registries can help adjusting treatment decisions and follow-up regimens in ROP. Our data collection will be continued as part of the newly established European ROP registry EU-ROP (www.eu-rop.org).

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept